Conference Day 1

10:15 am - 10:20 am PharmaIQ Welcome

10:20 am - 10:30 am Chairman's Opening Address

10:30 am - 11:15 am Cell and Gene Therapy Under Covid-19

  • Map the impact of Covid 19 across the Cell and Gene Industry and ascertain key areas of impact
  • Discuss the emergent challenges and opportunities in light of Covid-19 for CTG development and commercialisation
  • Analyse lessons learned in the past 4 months and how the industry can use this situation to better prepare for the future

11:15 am - 12:00 pm Optimising Cell Process of MCS's to Enhance ARDS and SARS-CoV-2 Specific T-cell Generation

Matthew Cobb - Clinical Account Manager, Miltenyi Biotech
  • Examine use cases demonstrate the versatility of the CliniMACS Prodigy® Platform in processing of MCS's
img

Matthew Cobb

Clinical Account Manager
Miltenyi Biotech

12:00 pm - 12:45 pm Building an Agile Operational Platform for Allogeneic Cell Therapies Under Covid-19

Lior Raviv - Vice President - Operations and Development, Pluristem Therapeutics
  • Hear how Pluristem have adjusted their operational platform from pre-Covid-19 to now and what they have done to increase platform adaptation and flexibility
  • Discuss building a flexible operational framework for allogeneic delivery in Israel and beyond
  • Examine ways in which Pluristem were able to adjust their logistical framework and supply networks to increase speed of response and decrease time to patient
img

Lior Raviv

Vice President - Operations and Development
Pluristem Therapeutics

12:45 pm - 2:00 pm Lunch Break

2:00 pm - 2:45 pm Session Reserved for Sponsor


2:45 pm - 3:45 pm Panel Discussion: Strategies to Maintain Development and Minimise Timeline Delays Under Covid-19

Louisa Mathias - Group Lead, Process Development and Manufacturing, GammaDelta Therapeutics
Matthew Cobb - Clinical Account Manager, Miltenyi Biotech
  • Identify opportunities to adapt your manufacturing and process development strategies to accommodate for the current climate
  • Debate the challenges present for materials management and sourcing with border closures and social distancing
  • Examine company strategies to minimise clinical and commercialization disruptions
  • Discuss key lessons learned under Covid-19 and what it may mean for industry development
img

Louisa Mathias

Group Lead, Process Development and Manufacturing
GammaDelta Therapeutics

img

Matthew Cobb

Clinical Account Manager
Miltenyi Biotech

3:45 pm - 4:30 pm Session Reserved for Sponsor


4:30 pm - 5:35 pm Close of Webinar Day 1